Prime links changes in adherence rates with total cost of care

Each step up in adherence links to a step down in total cost of care

April 21, 2021

Prime’s unique study of Medicare Advantage members uses integrated benefits data to show how each step up increase in adherence is associated with a step down decrease in total cost of care

Star Ratings are tied to adherence rates and specific chronic conditions. Prime wanted to understand more about the association between adherence rates and total cost of care for Star categories. Because of Prime’s connection to Blue Plans, Prime has integrated medical and pharmacy claims data and could track adherence rates to total cost of care.

Starting with a large Medicare population (over 560,000 members across 20 contracts) gave us strong cohorts to work with after applying analytic criteria. We looked at two years of data.

This study is rich with data you will not find anywhere else. It shows a statistically significant association between increasing adherence within Medicare Star Rating drug categories and lower total cost of care, as well as lower odds of hospitalizations and emergency department visits.

Every increase in adherence was associated with a decrease in total cost of care.

Each one percentage point adherence increase was associated with a cost-of-care decrease of $21 to $46 per patient per year. The specific dollar amount cost decrease varied by drug disease category. The most adherent individuals had lower annual total cost of care of between $1,353 and $3,713, depending on the drug disease category, compared to the least adherent individuals.

Findings are limited by potential healthy adherer effect.

Read more

Is Medicare Star Category Medication Adherence Associated with Lower Total Cost of Care and Medical Events? (Fall 2020)

Related news

Perspectives

November 28, 2022

Specialty Pipeline Quarterly Update: November 2022

This quarterly pipeline wrap-up provides a review of newly approved specialty drugs, recent…

Perspectives

November 18, 2022

Traditional Drug Pipeline Quarterly Update: November 2022

This quarterly pipeline wrap-up provides a review of newly approved traditional drugs, recent…

Perspectives

November 15, 2022

Three Minutes with Mitchell Scott

Mitchell Scott is Senior Director of Prime’s Special Investigations Unit (SIU) and Pharmacy…